vs

Side-by-side financial comparison of SILGAN HOLDINGS INC (SLGN) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.5B, roughly 1.0× SILGAN HOLDINGS INC). Steris runs the higher net margin — 12.9% vs 1.2%, a 11.7% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 4.1%). SILGAN HOLDINGS INC produced more free cash flow last quarter ($1.2B vs $199.5M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 5.6%).

Silgan Holdings Inc. is an American manufacturing company based in Connecticut that produces consumer goods packaging. The company was founded in 1987 by two former executives of Continental Can, Phil Silver and Greg Horrigan – their names contributing to the company name.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

SLGN vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.0× larger
STE
$1.5B
$1.5B
SLGN
Growing faster (revenue YoY)
STE
STE
+5.1% gap
STE
9.2%
4.1%
SLGN
Higher net margin
STE
STE
11.7% more per $
STE
12.9%
1.2%
SLGN
More free cash flow
SLGN
SLGN
$1.0B more FCF
SLGN
$1.2B
$199.5M
STE
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
5.6%
SLGN

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
SLGN
SLGN
STE
STE
Revenue
$1.5B
$1.5B
Net Profit
$18.2M
$192.9M
Gross Margin
17.2%
43.8%
Operating Margin
3.6%
18.3%
Net Margin
1.2%
12.9%
Revenue YoY
4.1%
9.2%
Net Profit YoY
-59.6%
11.2%
EPS (diluted)
$0.18
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLGN
SLGN
STE
STE
Q4 25
$1.5B
$1.5B
Q3 25
$2.0B
$1.5B
Q2 25
$1.5B
$1.4B
Q1 25
$1.5B
$1.5B
Q4 24
$1.4B
$1.4B
Q3 24
$1.7B
$1.3B
Q2 24
$1.4B
$1.3B
Q1 24
$1.3B
$1.1B
Net Profit
SLGN
SLGN
STE
STE
Q4 25
$18.2M
$192.9M
Q3 25
$113.3M
$191.9M
Q2 25
$88.9M
$177.4M
Q1 25
$68.0M
$145.7M
Q4 24
$45.1M
$173.5M
Q3 24
$100.1M
$150.0M
Q2 24
$76.1M
$145.4M
Q1 24
$55.2M
$-1.4M
Gross Margin
SLGN
SLGN
STE
STE
Q4 25
17.2%
43.8%
Q3 25
16.3%
44.2%
Q2 25
19.4%
45.1%
Q1 25
18.4%
43.3%
Q4 24
16.9%
44.5%
Q3 24
16.8%
43.6%
Q2 24
18.5%
44.7%
Q1 24
17.0%
40.2%
Operating Margin
SLGN
SLGN
STE
STE
Q4 25
3.6%
18.3%
Q3 25
7.4%
18.2%
Q2 25
7.7%
17.7%
Q1 25
6.0%
14.6%
Q4 24
3.4%
17.9%
Q3 24
7.2%
16.5%
Q2 24
7.3%
14.5%
Q1 24
5.5%
22.0%
Net Margin
SLGN
SLGN
STE
STE
Q4 25
1.2%
12.9%
Q3 25
5.6%
13.1%
Q2 25
5.8%
12.8%
Q1 25
4.6%
9.8%
Q4 24
3.2%
12.7%
Q3 24
5.7%
11.3%
Q2 24
5.5%
11.4%
Q1 24
4.2%
-0.1%
EPS (diluted)
SLGN
SLGN
STE
STE
Q4 25
$0.18
$1.96
Q3 25
$1.06
$1.94
Q2 25
$0.83
$1.79
Q1 25
$0.63
$1.48
Q4 24
$0.42
$1.75
Q3 24
$0.93
$1.51
Q2 24
$0.71
$1.46
Q1 24
$0.52
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLGN
SLGN
STE
STE
Cash + ST InvestmentsLiquidity on hand
$1.1B
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$2.3B
$7.2B
Total Assets
$9.4B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLGN
SLGN
STE
STE
Q4 25
$1.1B
$423.7M
Q3 25
$389.2M
$319.2M
Q2 25
$317.5M
$279.7M
Q1 25
$353.0M
$171.7M
Q4 24
$822.9M
$155.2M
Q3 24
$368.5M
$172.2M
Q2 24
$302.8M
$198.3M
Q1 24
$308.6M
$207.0M
Total Debt
SLGN
SLGN
STE
STE
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
SLGN
SLGN
STE
STE
Q4 25
$2.3B
$7.2B
Q3 25
$2.3B
$7.0B
Q2 25
$2.2B
$7.0B
Q1 25
$2.1B
$6.6B
Q4 24
$2.0B
$6.4B
Q3 24
$2.1B
$6.6B
Q2 24
$1.9B
$6.4B
Q1 24
$1.9B
$6.3B
Total Assets
SLGN
SLGN
STE
STE
Q4 25
$9.4B
$10.6B
Q3 25
$9.5B
$10.4B
Q2 25
$9.4B
$10.4B
Q1 25
$8.8B
$10.1B
Q4 24
$8.6B
$10.0B
Q3 24
$7.7B
$10.2B
Q2 24
$7.7B
$10.1B
Q1 24
$7.6B
$11.1B
Debt / Equity
SLGN
SLGN
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLGN
SLGN
STE
STE
Operating Cash FlowLast quarter
$1.3B
$298.2M
Free Cash FlowOCF − Capex
$1.2B
$199.5M
FCF MarginFCF / Revenue
83.2%
13.3%
Capex IntensityCapex / Revenue
4.9%
6.6%
Cash ConversionOCF / Net Profit
71.07×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$422.7M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLGN
SLGN
STE
STE
Q4 25
$1.3B
$298.2M
Q3 25
$340.9M
$287.8M
Q2 25
$-221.4M
$420.0M
Q1 25
$-683.4M
$260.8M
Q4 24
$935.8M
$332.8M
Q3 24
$313.0M
$250.7M
Q2 24
$20.9M
$303.7M
Q1 24
$-547.8M
$254.8M
Free Cash Flow
SLGN
SLGN
STE
STE
Q4 25
$1.2B
$199.5M
Q3 25
$260.8M
$201.3M
Q2 25
$-294.2M
$326.4M
Q1 25
$-766.3M
$189.9M
Q4 24
$865.0M
$243.6M
Q3 24
$252.4M
$148.8M
Q2 24
$-35.3M
$195.7M
Q1 24
$-623.1M
$163.3M
FCF Margin
SLGN
SLGN
STE
STE
Q4 25
83.2%
13.3%
Q3 25
13.0%
13.8%
Q2 25
-19.1%
23.5%
Q1 25
-52.2%
12.8%
Q4 24
61.3%
17.8%
Q3 24
14.5%
11.2%
Q2 24
-2.6%
15.3%
Q1 24
-47.3%
14.6%
Capex Intensity
SLGN
SLGN
STE
STE
Q4 25
4.9%
6.6%
Q3 25
4.0%
5.9%
Q2 25
4.7%
6.7%
Q1 25
5.7%
4.8%
Q4 24
5.0%
6.5%
Q3 24
3.5%
7.7%
Q2 24
4.1%
8.4%
Q1 24
5.7%
8.2%
Cash Conversion
SLGN
SLGN
STE
STE
Q4 25
71.07×
1.55×
Q3 25
3.01×
1.50×
Q2 25
-2.49×
2.37×
Q1 25
-10.06×
1.79×
Q4 24
20.77×
1.92×
Q3 24
3.13×
1.67×
Q2 24
0.27×
2.09×
Q1 24
-9.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SLGN
SLGN

Metal Containers$675.6M46%
Dispensing And Specialty Closures$643.6M44%
Custom Containers$149.4M10%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons